Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Frontage Laboratories, a provider of bioanalytical, pre-clinical and drug development services, has acquired Advanced Biomedical Research.
Subscribe to our email newsletter
Frontage made an initial 20% equity investment in Advanced Biomedical Research (ABR) in 2007 and acquires the remaining 80% equity with the completion of this transaction.
Frontage and ABR now offer formulation development, bioanalytical and manufacturing practices testing services, Phase I-II study performance in a 72-bed clinical research center, and international Phase II-IV contract research organization (CRO) services.
The combined resources of Frontage and ABR are expected to offer clients a single source for clinical, bioanalytical and drug development services, integrated program management from discovery to commercialization, cost-effective, collaborative R&D services, proven management team and proactive client-centric focus.
Song Li, chairman and CEO of Frontage and newly appointed chairman of ABR, said: “With our R&D services expertise in the US and China, and ABR’s turn-key clinical CRO services for conducting and managing Phase I-IV clinical trials, the addition of ABR to the Frontage family allows us to offer a full spectrum of clinical testing and R&D pharmaceutical services to our clients.”